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Abstract
Objective To evaluate potential MRI-defined effect modifiers of amoxicillin treatment in patients with chronic low back pain and
type 1 or 2 Modic changes (MCs) at the level of a previous lumbar disc herniation (index level).
Methods In a prospective trial (AIM), 180 patients (25–64 years; mean age 45; 105 women) were randomised to receive
amoxicillin or placebo for 3 months. Primary outcome was the Roland-Morris Disability Questionnaire (RMDQ) score (0–24
scale) at 1 year. Mean RMDQ score difference between the groups at 1 year defined the treatment effect; 4 RMDQ points defined
the minimal clinically important effect. Predefined baseline MRI features of MCs at the index level(s) were investigated as
potential effect modifiers. The predefined primary hypothesis was a better effect of amoxicillin when short tau inversion recovery
(STIR) shows more MC-related high signal. To evaluate this hypothesis, we pre-constructed a composite variable with three
categories (STIR1/2/3). STIR3 implied MC-related STIR signal increases with volume ≥ 25% and height > 50% of vertebral
body and maximum intensity increase ≥ 25% and presence on both sides of the disc. As pre-planned, interaction with treatment
was analysed using ANCOVA in the per protocol population (n = 155).
Results The STIR3 composite group (n = 41) and STIR signal volume ≥ 25% alone (n = 45) modified the treatment effect of
amoxicillin. As hypothesised, STIR3 patients reported the largest effect (− 5.1 RMDQ points; 95% CI − 8.2 to − 1.9; p for
interaction = 0.008).
Conclusions Predefined subgroups with abundant MC-related index-level oedema on STIR modified the effect of amoxicillin.
This finding needs replication and further support.
Key Points
• In the primary analysis of the AIM trial, the effect of amoxicillin in patients with chronic low back pain and type 1 or 2 MCs did
not reach the predefined cut-off for clinical importance.
• In the present MRI subgroup analysis of AIM, predefined subgroups with abundant MC-related oedema on STIR reported an
effect of amoxicillin.
• This finding requires replication and further support.
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AIM Antibiotics in Modic changes
CI Confidence interval
ITT Intention to treat
LBP Low back pain
MCs Modic changes
MRI Magnetic resonance imaging
ODI Oswestry Disability Index
PP Per protocol
RMDQ Roland-Morris Disability Questionnaire
STIR Short tau inversion recovery
T1/T2 T1- and T2-weighted fast spin echo images
Introduction
Modic changes (MCs) are magnetic resonance imaging (MRI)
findings of vertebral bonemarrow changes extending from the
endplate. MCs are defined as type 1 (oedema type), 2 (fatty
type), and 3 (sclerotic type) based on their intensity on T1- and
T2-weighted MRI [1, 2]. However, the MC intensity and type
depend on MRI scanning parameters and magnetic field
strength [3, 4], and different MC types may represent stages
of a common biological process [5]. This process may involve
inflammation, fibrosis, high bone turnover, fatty infiltration,
and sclerosis [1, 5, 6]. MCs were related to low back pain
(LBP) in some studies but not in others [7–9]. The evidence
for an association betweenMCs and LBP is stronger for type 1
than for type 2 or 3 MCs [10–15]. Proposed explanations for
MCs include endplate damage, autoimmunity, and occult
discitis [5]. Vertebral bone oedema resembling type 1 MCs
is a common MRI finding in spondylodiscitis [16], and one
theory is that MCs develop adjacent to a low-grade discitis
region caused by haematogenic spread of Cutibacterium
acnes bacteria to a previously disrupted, neo-vascularised
lumbar disc [17, 18].
A previous trial reported a substantial effect of antibiotic
treatment for chronic LBP with type 1 MCs on 0.2-T MRI
[19]. Some of these MCs might have appeared as type 2 on
1.5-T MRI [4]. The recent AIM (Antibiotics In Modic chang-
es) trial applied 1.5-T MRI [20] and reported a small but not
clinically important effect of amoxicillin in chronic LBP pa-
tients with type 1 MCs (− 2.3 points on the Roland-Morris
Disability Questionnaire (RMDQ)) and no effect for type 2
MCs (− 0.1 RMDQ points) [21]. Thus, the type 1 (oedema
type) group tended to have a larger effect. More bone marrow
oedema may be associated with worse pain and disability
[22–24] and might indicate more severe disease with a larger
potential for improvement. Therefore, we hypothesised a larg-
er effect of amoxicillin in subgroups with more versus less
MC-related oedema. It is relevant to assess subgroup effects
across both MC types because both can contain inflammatory
changes [25] and oedema [26].
Short tau inversion recovery (STIR) series are ideal for
highlighting oedema. STIR suppresses a high signal from fat
and often shows oedema inMCs classified as type 2 on T1/T2
series without fat suppression [26]. Although STIR is more
sensitive to bone marrow oedema than standard T1/T2 series
[26, 27], STIR can likewise not separate infectious from non-
infectious causes [28, 29]. This subgroup study of the AIM
trial included both STIR and standard fast spin echo T1/T2
sequences.We aimed to evaluate potential MRI-defined effect
modifiers of amoxicillin treatment in patients with chronic
LBP and type 1 or 2 MCs at the level of a previous lumbar
disc herniation.
Materials and methods
The AIM trial included 180 patients from six hospital outpa-
tient clinics in Norway from June 2015 to September 2017
[20, 21]. All the eligibility criteria are detailed in the
Appendix, Table A1. The inclusion criteria were age 18–
65 years, LBP for more than 6 months with a mean intensity
of at least 5 on three 0–10 numerical rating scales, lumbar disc
herniation onMRI in the preceding 2 years, and type 1 or type
2 MCs (with height ≥ 10% of the vertebral height and diame-
ter > 5 mm) at the previously herniated disc level. Trial flow
chart, trial methods, and baseline characteristics are published
[21]. The trial, this study, and statistical analysis plans are
registered at ClinicalTrials.gov (identifier: NCT02323412).
Randomisation, treatment, and outcome measures
Patients were randomised to receive oral amoxicillin 750 mg
or placebo (maize starch) three times daily for 3 months. The
amoxicillin and placebo tablets had identical encapsulation,
containers, and labelling. A third-party statistician used Stata
13 (StataCorp) to create randomisation lists. Allocation was
stratified by prior disc surgery (yes/no) and MC type (type 1
(n = 118) or type 2 (n = 62) only) at the previously herniated
disc level(s) with a 1:1:1:1 allocation and random block sizes
of four and six [21]. The allocation sequence was concealed
and centrally administered. Care providers gave patients a
prescription with a computer-generated allocation number to
be used at dedicated pharmacies. All care providers, research
staff, statisticians, and patients were blinded to treatment allo-
cation during data collection.
The primary endpoint was the RMDQ score (0–24 scale) at
1 year [30, 31]. The minimal clinically important difference in
mean RMDQ score at 1 year between treatment groups (treat-
ment effect) was predefined as 4 [20, 21]. The outcome at the
end of the treatment period (3 months) was not primary be-
cause long-term improvement is desirable and the antibiotic
group in the prior trial improved by 4.5 RMDQ points (0–23
scale) from the end of the treatment period to 1 year [19]. The
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Oswestry Disability Index (ODI) 2.0 (0–100 scale) [32] and
LBP intensity (0–10 numeric rating scale) were secondary
outcomes [21].
MRI assessment
Baseline MRI of the lumbar spine was performed at six cen-
tres using identical protocols and the same type of 1.5-T scan-
ner with the same software version (Magnetom Avanto B19;
Siemens). This MRI included sagittal T1- and T2-weighted
fast spin echo (‘T1/T2’) and sagittal STIR images. The inte-
grated spine array coil was used, but no surface coils. Echo
time (ms)/repetition time (ms) was 11/575 for T1, 87/3700 for
T2, and 70/5530 for STIR. Echo train length was 5 for T1, 17
for T2, and 20 for STIR. Matrix was 384 × 269 for T1/T2 and
320 × 224 for STIR. The inversion time for STIR was 160 ms.
Slice thickness/spacing was 4 mm/0.4 mm and field of view
was 300 mm× 300 mm for all three sequences. Other MRI
parameters were also identical between centres [33].
Three radiologists (A.E., N.V., and P.M.K.) who were
blinded to clinical outcomes and treatment allocation indepen-
dently rated MRI findings [33]. All had > 10 years of experi-
ence in musculoskeletal MRI. The same three radiologists
interpreted the MRIs from all study centres. On T1/T2, they
rated primary (most extensive) and secondary MC types as
type 1 (hypointense on T1, hyperintense on T2), type 2 (hy-
perintense on T1, iso- or hyperintense on T2), and type 3
(hypointense on T1 and T2) [33]. They evaluated the largest
height and volume of MCs on T1/T2 and the largest height,
volume and intensity of any MC-related STIR signal increase
(Table 1), defined as a visible increase compared with normal
vertebral bone marrow, located in or abutting a region with
MC on T1/T2 or located and shaped as an MC [33].
We based the conclusive MRI findings on the radiologists’
majority rating or mean value of measurements made by two
of them (A.E. and P.M.K. if all three agreed there was a lesion
to measure). The inter-rater reliability of the MRI evaluations
was previously reported [33]. Fleiss’ kappa values [34] for
overall inter-rater agreement (mean values across four
Table 1 Predefined MRI variables at index level(s) with type 1 or 2 MCs and prior disc herniation
Description Analysed subgroups
STIR signal extent and intensity
STIR volume Largest volume of high STIR signal in % of vertebral body marrow
volume, visually estimated (not measured), and scored as 0, 1
(< 10%), 2 (< 25%), 3 (25–50%), or 4 (> 50%)
Scores 0–1, 2, and 3–4
STIR height Maximum height of region with high STIR signal, measured and
recalculated into a percentage of vertebral body marrow height
Analysed as a continuous variable and
dichotomised into ≤ 50% and > 50%
STIR intensity Maximum intensity of the high STIR signal, measured as a
percentage on a scale from normal vertebral body marrow
intensity (0%) to cerebrospinal fluid intensity (100%)
< 25%, 25–40%, and > 40%a
STIR sup/inf Presence of high STIR signal both superior (sup) and inferior (inf)
to index disc (yes/no)
Yes and no
STIR composite Categorised as STIR3 (volume ≥ 25% AND height > 50% AND
intensity ≥ 25% AND yes for sup/inf), STIR2 (not STIR3 or
STIR1) and STIR1 (volume < 25% AND intensity < 25%)
STIR1, STIR2, and STIR3
MC type and extent on T1/T2
MC type 1 degree Categorised as type 1 major (primary type 1 both superior and
inferior to disc), type 1 minor (primary or secondary type 1, but
not type 1 major), and type 2 only (not type 1)
Type 2 only, type 1 minor, and type 1 major
MC volume Largest volume of MC (including all MC types) in % of vertebral
body marrow volume, visually estimated, and scored as 0, 1
(< 10%), 2 (< 25%), 3 (25–50%), or 4 (> 50%)
Scores 1, 2, and 3–4 (not score 0; conclusive
MC volume cannot be 0 at an index level)
MC height Maximum MC height (including all MC types), measured and
recalculated as a percentage of vertebral body marrow height
Analysed as a continuous variable and
dichotomised into ≤ 50% and > 50%
MC composite Categorised as 1++ (type 1 major AND volume ≥ 10%—OR—
primary type 1 AND volume ≥ 25% AND height ≥ 50% AND
yes for sup/inf), 1+ (primary or secondary type 1 but not type
1++) and type 2 only
Type 2 only, 1+, and 1++
MRI, magnetic resonance imaging; MCs, Modic changes; STIR, short tau inversion recovery; T1/T2, T1- and T2-weighted fast spin echo images
a STIR intensity < 25% included MCs with no conclusive STIR signal increase (or decreased STIR signal) and thus no conclusive measured STIR
intensity values. These values had likely been < 25% if measured, since the STIR intensity was < 20% for > 90% of intensity measurements reported by
only one radiologist (as the other radiologists found no visual signal increase and therefore did not measure STIR intensity). To enhance clinical
credibility, images were reviewed to ensure that intensity ≥ 25% implied visually convincing hyper-intensity
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endplates L4-S1) were 0.88/0.81 for presence of any MCs/
type 1 MCs, 0.64/0.69 for MC height/volume, 0.86 for pres-
ence of a STIR signal increase, and 0.51/0.56 (0.40/0.40 at L5/
S1 inferior to disc) for STIR signal height/volume. For max-
imum MC-related STIR signal intensity on a 0–100% scale
(0% = normal vertebral body; 100% = cerebrospinal fluid),
largest mean of differences and widest 95% limits of agree-
ment were 0.9% and ± 7.6%, respectively.
Predefined hypotheses and potential effect modifiers
In the AIM trial protocol, we hypothesised a better effect of
amoxicillin when:
– STIR shows more MC-related high signal (primary
hypothesis)
– MCs contain more type 1 than type 2 or are larger (ex-
plorative hypothesis)
The nine variables described in Table 1 were predefined
as potential effect modifiers in the statistical analysis plan.
All concerned MCs at the index level(s) with prior disc
herniation because this level was hypothesised to contain
low-grade discitis that was the target for treatment. One
composite and four underlying variables concerned STIR
signal extent and intensity. The STIR composite variable
had three categories (STIR1/2/3) and was used to assess
the primary hypothesis. STIR3 implied MC-related STIR
signal increase with volume ≥ 25% and height > 50% of the
vertebral body, maximum intensity increase ≥ 25%, and
presence on both sides of the disc. One composite and
three underlying variables concerned MC extent and type
1 degree on T1/T2. We constructed each composite vari-
able by clinically plausible grouping of the underlying var-
iables [35]. We did so before analysing the effect of any
MRI variable on the outcome but were not blinded to the
distribution of the variables in our sample.
Analyses
The baseline properties of the randomised groups were
characterised using descriptive methods.
All pre-planned analyses are described in Table 2. Each
effect modifier was analysed using ANCOVA with the out-
come (RMDQ, ODI, or LBP intensity) at 1 year as the depen-
dent variable and the randomisation group, effect modifier,




ANCOVAa—dependent variable: RMDQ score at 1 year; independent variables: baseline RMDQ score, the potential effect
modifier, treatment group, their interaction term (effect modifiera treatment), age, former disc herniation surgery
PP and ITT
ANCOVAa—as above with ODI score replacing RMDQ score PP and ITT
ANCOVAa—as above with LBP intensity score replacing RMDQ score PP and ITT
ANCOVAa—to assess the independency of any effect modification for STIR composite and/or MC composite; dependent
variable: RMDQ score at 1 year; independent variables: baseline RMDQ score, STIR composite, MC composite, age,
treatment, STIR composite*treatment, MC composite*treatment, age*treatment, former disc herniation surgery
PP
Post hoc analyses—to evaluate STIR3 results
Comparison of treatment groups—baseline factors, concomitant treatment; no statistical testing STIR3 group
Responder analyses—number needed to treat to achieve > 30%, > 50%, and > 75% reduced RMDQ score from baseline to
1 year (for those with complete data)
STIR3 group with
data
Distribution of responders—number and proportions of patients with > 30%, > 50%, and > 75% reduced RMDQ score at 1 year
(those with complete data) by treatment group and STIR group
All with data
Linear mixed-effects models—to assess treatment effect over time; using Akaike’s information criterion to decide which
covariance matrix to apply; dependent variable: RMDQ (5 time points), ODI (3 time points), or LBP intensity (17 time points);
independent variables: time, treatment, time*treatment, age, prior disc herniation surgery
PP STIR3 group
Scatterplot of change in RMDQ score—to visualise change in RMDQ score from baseline to 1 year in each treatment group for
STIR1, STIR2, and STIR3 patients (those with complete data)
PP with data
Bangs blinding index—for each treatment group based on their response at 1 year to ‘Which study medicine do you think you
received?’ (antibiotics/placebo/unsure); range: − 1 (all report incorrect treatment) to 1 (all report the correct treatment); 0 =
random reporting of treatment
STIR3 group
PP, per protocol; ITT, intention to treat; RMDQ, Roland-Morris Disability Questionnaire; ODI, Oswestry Disability Index; LBP, low back pain; STIR,
short tau inversion recovery; MC, Modic change
aMissing values of RMDQ, ODI, or LBP intensity were substituted with imputed values from the multiple imputations performed in the trial. This
multiple imputation model used 50 imputations, predictive mean matching, and the following predictors: age, leg pain, comorbidity, fear avoidance,
emotional distress, physical workload, former surgery for disc herniation, study centre, MC type group, and treatment group
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and their interaction as independent variables adjusted for the
baseline values of the outcome. Additionally, we adjusted for
age and prior disc surgery because contamination during sur-
gery is a potential cause of discitis. Supporting the use of
ANCOVA, Levene’s test indicated homogeneity of variances,
and QQ plots indicated normally distributed residuals and
outcome variables without extreme outliers. If one or both
composite MRI variables modified the treatment effect, we
would include both in the same model to assess their
independence [36]. Post hoc analyses, marked as such
throughout the manuscript, are also described in Table 2.
The primary analyses were performed on the predefined
per protocol (PP) population described in the Appendix, page
2. The intention to treat (ITT) population was used for sup-
portive analyses. Missing outcome values were imputed using
multiple imputation (details in footnote, Table 2).
We used a Bonferroni-corrected alpha of 0.05/6 (0.008)
when testing the primary hypothesis (ranked as hypothesis
Table 3 Baseline index level MRI findings by treatment group in the total sample (N = 180)
Amoxicillin group (N = 89) Placebo group (N = 91)
Variable n % n %
STIR composite
STIR1 23 25.8 25 27.5
STIR2 42 47.2 45 49.5
STIR3 24 27.0 21 23.1
STIR volume—maximum score (% of vertebral body marrow volume; visually estimated)
0 (0%) 11 12.4 5 5.5
1 (< 10%) 21 23.6 27 29.7
2 (< 25%) 31 34.8 36 39.6
3 (25–50%) 21 23.6 18 19.8
4 (> 50%) 5 5.6 5 5.5
STIR height—% of vertebral body marrow height
Median (interquartile range) 51 (32–63) 51 (38–62)
< 25 15 16.9 11 12.1
25–50 28 31.5 34 37.4
> 50 46 51.7 46 50.5
STIR intensity—% increase from normal vertebral body intensity (0%) to CSF intensity (100%)
Mean (SD) 39 (14) 35 (14)
< 25 25 28.1 27 29.7
25–40 26 29.2 31 34.1
> 40 38 42.7 33 36.3
STIR sup/inf—STIR signal increase both superior and inferior to disc
Yes 72 80.9 78 85.7
No 17 19.1 13 14.3
MC composite
Type 2 only 31 34.8 31 34.1
1+ 19 21.3 36 39.6
1++ 39 43.8 24 26.4
MC type I degree—categories
Type 2 only 31 34.8 31 34.1
Type 1 minor 24 27.0 43 47.3
Type 1 major 34 38.2 17 18.7
MC volume—maximum score (% of vertebral body marrow volume; cannot be 0%)
1 (< 10%) 17 19.1 15 16.5
2 (< 25%) 33 37.1 35 38.5
3 (25–50%) 30 33.7 29 31.9
4 (> 50%) 9 10.1 12 13.2
MC height—% of vertebral body marrow height
Mean (SD) 51 (16) 49 (16)
< 25 5 5.6 6 6.6
25–50 39 43.8 45 49.5
> 50 45 50.6 40 44.0
Index level(s) with MC and previous disc herniation
L2/L3 2 2.2 2 2.2
L3/L4 7 7.9 5 5.5
L4/L5 48 53.9 29 31.9
L5/S1 58 65.2 74 81.3
MRI, magnetic resonance imaging; STIR, short tau inversion recovery; SD, standard deviation;MC, Modic change. MC variables are based on T1- and
T2-weighted fast spin echo images, not STIR
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six in the trial protocol) [20]. Otherwise, an alpha of 0.05 was
applied to minimise type 2 errors [37]. Analyses were per-
formed using Stata 16 (StataCorp), and figures were made
using MATLAB 9.5 (MathWorks) or Stata 16.
Power calculation
The AIM trial was designed with 90% power in eachMC type
group [20]; 80% power in the total sample would have re-
quired 50 patients or 200 patients in a subgroup study with
two equally large subgroups [38]. In this study with three
subgroup categories, 80% power would have required > 200
patients. Adding covariates in the analyses improved the pow-
er [39], but our sample was still small.
Results
The 180 patients were aged 25–64 years (mean age 45 years;
standard deviation 9 years); 105 (58%) patients were women.
Table 3 shows baseline MRI findings by treatment group. Of
360 baseline and 1-year outcome values, 13 were missing for
RMDQ, 14 for ODI, and 13 for LBP intensity. The results for
the effect modifiers were similar in PP analyses (n = 155)
(Figs. 1, 2, and 3) and ITT analyses (n = 180) (Appendix,
Figs. A1–A3).
Primary hypothesis—STIR
As hypothesised, the STIR3 group (n = 41) reported the larg-
est effect of amoxicillin; the difference in mean RMDQ score
at 1 year between those receiving amoxicillin and those re-
ceiving placebo (PP analysis) was − 5.1 (95% CI − 8.2 to −
1.9, p for interaction = 0.008) (Fig. 1). The corresponding dif-
ference was − 0.7 (95% CI − 3.1 to 1.7) in the STIR2 group
and 1.1 (95% CI − 2.1 to 4.4) in the STIR1 group. The treat-
ment effect in the STIR3 group was − 4.8 points (95% CI −
7.9 to − 1.8; p for interaction = 0.014) in the ITT analysis and
− 4.5 RMDQ points (95%CI − 7.9 to − 1.1, p for interaction =
Fig. 1 Roland-Morris Disability Questionnaire (RMDQ) for all effect
modifiers (per protocol). RMDQ scores range from 0 (no disability) to
24 (maximum disability). Observed difference between treatment groups
(mean ± 95%CI) and estimated coefficients (with 95%CI) for interaction
from the ANCOVA (per protocol) with p values. PP, per protocol; CI,
confidence interval; STIR, short tau inversion recovery; MC, Modic
change. MC variables are based on T1- and T2-weighted fast spin echo
images, not STIR
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0.14) in the PP model including both composite MRI
variables.
STIR volume ≥ 25% of the vertebral body (n = 45) also
significantly modified the treatment effect (Fig. 1). In the
STIR3 and STIR volume ≥ 25% groups, the effect of amoxi-
cillin was > 4 RMDQ points (cut-off for clinical importance)
and also evident for ODI (Fig. 2) but not for LBP intensity
(Fig. 3).
Explorative hypothesis—T1/T2
The results for the composite MC variable based on T1/
T2 did not reach statistical significance or clinical impor-
tance (Fig. 1). Two underlying subgroups significantly
modified the treatment effect in favour of amoxicillin:
MC volume ≥ 25% and MC height > 50% of the verte-
bral body (Fig. 1). The treatment effect within these sub-
groups did not exceed the threshold for clinical
importance.
Post hoc analyses of STIR3
The baseline characteristics of the STIR3 patients were similar
in both treatment groups (Appendix, Table A5). The STIR3
patients and total sample had similar mean baseline RMDQ
scores (amoxicillin/placebo 12.8/12.6 vs. 12.7/12.8) and prior
disc surgery rates (16% vs. 21%).
The number of STIR3 patients needed to be treated to
achieve > 30% improved RMDQ score at 1 year was 3.1
(95% CI 1.7 to 27) (Appendix, Tables A2–A3). Among pa-
tients receiving amoxicillin, 6 of 22 STIR3 patients (27%)
improved > 75% compared with 9 of 41 (22%) STIR2 patients
and no STIR1 patients.
The treatment effect of amoxicillin in the STIR3 group was
present at 3 months and remained until the end of the study at
1 year (Fig. 4), but the change in RMDQ score varied consid-
erably between patients (Fig. 5).
Bangs blinding index for STIR3 patients was − 0.01 in the
amoxicillin group, indicating perfect blinding, and 0.61 in the
placebo group, indicating un-blinding (Appendix, Table A4).
Fig. 2 Oswestry Disability Index (ODI) for all effect modifiers (per pro-
tocol). ODI scores range from 0 (no disability) to 100 (maximum disabil-
ity). Observed difference between treatment groups (mean ± 95%CI) and
estimated coefficients (with 95% CI) for interaction from the ANCOVA
(per protocol) with p values. Missing value not imputed in one patient
(excluded). PP, per protocol; CI, confidence interval; STIR, short tau
inversion recovery; MC, Modic change. MC variables are based on T1-
and T2-weighted fast spin echo images, not STIR
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Discussion
To our knowledge, this was the first study to investigate STIR-
based effect modifiers of a treatment for chronic LBP with
MCs. These effect modifiers were defined byMC-related high
signal on STIR at the previously herniated index level(s)
hypothesised to contain a low-grade discitis. The STIR3 and
STIR volume ≥ 25% groups with abundant high signal mod-
ified the treatment effect of amoxicillin. STIR3 patients re-
ported the largest effect (− 5.1 RMDQ points; 95% CI − 8.2
to − 1.9; p for interaction = 0.008). Subgroups based on T1/T2
features of MCs did not report a clinically important effect of
amoxicillin. All subgroups were small, and the findings must
be interpreted with caution.
Credibility of results
We consider the subgroup effect of STIR3 to have overall
moderate credibility based on the criteria predefined in the
statistical analysis plan [36] and the results of the post hoc
analyses, but some criteria were not fulfilled (Table 4). The
interaction of STIR3 and STIR volume ≥ 25% with treatment
was found for the related outcomes RMDQ and ODI but not
for LBP, and the finding has not yet been replicated in other
studies. No tissue samples were taken, and STIR findings
alone are not diagnostic for infection [28, 29]. Further data
are needed to link extensive oedema on STIR to low-grade
disc infection.
Post hoc responder analyses supported an effect of amox-
icillin in the STIR3 group, but the estimates showed wide CIs
(Appendix, Tables A2–A3). Similar to patients with verified
Cutibacterium acnes discitis [40], STIR3 patients improved
most during antibiotic treatment (Fig. 4). The clinical course
in the STIR3 placebo group is difficult to evaluate for credi-
bility because the natural course in untreated groups with
abundant MC-related oedema on STIR is unknown. The
STIR3 placebo group reported almost no improvement during
the 1-year follow-up (Fig. 4). Placebo groups and sick-listed
Fig. 3 Low back pain intensity for all effect modifiers (per protocol). Pain
intensity scores range from 0 (no pain) to 10 (worst possible pain).
Observed difference between treatment groups (mean ± 95% CI) and
estimated coefficients (with 95% CI) for interaction from the ANCOVA
(per protocol) with p values. Missing value not imputed in one patient
(excluded). PP, per protocol; CI, confidence interval; STIR, short tau
inversion recovery; MC, Modic change. MC variables are based on T1-
and T2-weighted fast spin echo images, not STIR
Eur Radiol
patients with persistent LBP and type 1 MCs also reported
little improvement over 1 year in some studies: 0.5–1.4 points
for RMDQ [19, 41, 42], 1.9 points for ODI [43], and 0–2.2
points for LBP [19, 41–43].
Incomplete blinding may have contributed to lack of im-
provement in our placebo group and an overestimated effect
of amoxicillin. All patients were blinded to treatment alloca-
tion, but placebo patients still tended to suspect they were not
on active treatment (Table A4). This might be due to a lack of
treatment effect or lack of side effects [44]. AIM patients with
little improvement at 3 months and no side effects were less
likely to report at 1 year that they had received antibiotics [21].
The precise impact of incomplete blinding on outcome is un-
clear [45].
As hypothesised, amoxicillin had the largest effect on
RMDQ and ODI in the assumed ‘worst’ category of all
STIR variables (Figs. 1 and 2). This was not the case in the
type 1 major category on T1/T2, and the effect of placebo in
the group ‘MC volume <10%’ is difficult to explain and may
be spurious (Fig. 1). Thus, the results for STIR variables ap-
pear more credible than the explorative T1/T2 results. Below,
we further discuss the STIR3 results that correspond to our
predefined primary hypothesis.
STIR3 results—interpretation and implications
The effect of amoxicillin was larger for STIR3 patients than
for the original type 1 and type 2 onlyMCgroups (− 2.3 and −
0.1 RMDQ points, respectively) in the primary analysis of
AIM [19]. The disability at baseline was similar, not worse
in the STIR3 group as expected, and cannot explain the dif-
ference. These findings make it relevant to examine patients
with extensive MC-related oedema on STIR as a separate
subgroup in future treatment studies.
Fig. 4 Treatment effect over time
for STIR3 patients (per protocol).
Roland-Morris Disability
Questionnaire score (0–24 scale),
Oswestry Disability Index score
(0–100 scale), and low back pain
intensity (0–10 numerical rating
scale) from baseline to 1 year in
each treatment group. Higher
scores imply worse disability/
pain. The results are from post
hoc analyses
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It remains unclear why the treatment effect (RMDQ differ-
ence) at 1 year was smaller in the STIR3 group (5.1; 0–24
scale) than in the prior cohort with type 1 MCs (8.3; 0–23
scale) [19]. Baseline MC oedema cannot be compared be-
cause the prior trial applied 0.2-T MRI without STIR. Both
cohorts had MCs at the level of a prior disc herniation. STIR3
patients had slightly lower baseline RMDQ scores than the
previous cohort, less than 13 vs. 15 [19]; baseline LBP scores
were similar, above 6.
The STIR3 results were consistent with the hypothesis that
some MCs with abundant oedema on STIR might represent
low-grade discitis. Importantly, spondylodiscitis was an ex-
clusion criterion and was not suspected on MRI. The STIR3
findings were credible by most of the predefined criteria
(Table 4) and the treatment course mirrored that of
Cutibacterium acnes discitis.
However, replication of our findings is essential. The effect
of amoxicillin in the STIR3 group varied greatly (Fig. 5) and
was not evident for LBP intensity. The CI overlapped with the
cut-off for clinical importance, bacterial infection was not ver-
ified, and un-blinding may have occurred. Additionally, ad-
verse events and antibiotic resistance are potential harms [21].
The present findings support the use of STIR to evaluate
MCs. They also motivate further studies of MC-related oede-
ma on STIR in relation to possible biological markers of in-
fection that are currently being investigated by our research
group. To achieve an optimal classification of MCs for poten-
tial clinical use, MC characteristics not studied here, such as
diffusion parameters [46], contrast enhancement, and bone
turnover [6], should also be investigated.
Further work is needed to quantify STIR findings. The
composite STIR variable was based on both visual assess-
ments and several time-consuming manual measurements.
The visually estimated STIR signal volume alone yielded sim-
ilar results and might be more applicable in a clinical setting.
However, precise measurements are preferable in research and
may become more feasible with advanced automated tech-
niques [47, 48]. To date, few studies have quantified spinal
oedema on MRI [29, 49–51].
Strengths and limitations
The strengths of this study include predefined hypotheses,
standardised MRI techniques, and MRI ratings by three expe-
rienced radiologists [52]. Additionally, potential effect modi-
fiers were defined and categorised before analysing their mod-
ifying impact.
Subgroup studies of clinical trials often have limited
statistical power and generalisability [36, 53, 54]. This
phenomenon also applies to our study. Our pre-decision
in the statistical analysis plan to perform primary PP anal-
yses is debatable, although we also present secondary ITT
results. The decision implied that we focused primarily on
the effect of amoxicillin and secondarily on the effect of
allocating patients to receive amoxicillin [55, 56]. The im-
pact of MRI findings on the treatment effect in patients
who did not follow their assigned treatment seemed less
relevant to study. PP analyses can create prognostic differ-
ences between the treatment groups [55]. However, ITT
analyses supported the PP findings.
We evaluated the MRIs at inclusion before defining the
subgroups, and the definitions of the MRI subgroups were
partly dependent on the MRI data [57]. Furthermore, the com-
posite MRI variables had not been validated. The ratings of
STIR signal height and volume were less reliable at L5/S1
inferior to the disc [33]. However, the conclusive rating based
on multiple observers’ evaluations was likely more reliable
than each observer’s rating [52]. When an MC contained both
type 1 and another type, we classified the type 1 part as pri-
mary or secondary, but we did not measure its exact size or
intensity. Our results may not apply to low-field or 3-T MRI.
However, they are likely valid with similar 1.5-T MRI proto-
cols [3] and STIR works well with both low- and high-field
scanners [58, 59].
Conclusion
Predefined subgroups with chronic LBP, an index level with
prior disc herniation, and abundant MC-related index-level
oedema on STIR modified the treatment effect of amoxicillin.
Fig. 5 Change in the Roland-Morris Disability Questionnaire (RMDQ)
score (per protocol). The change in the RMDQ score (0–24 scale) from
baseline to 1 year in each treatment group is plotted for STIR1, STIR2,
and STIR3 patients; negative values denote improvement. The results are
from post hoc analyses. STIR, short tau inversion recovery
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This finding shows moderate credibility based on published
criteria and post hoc analyses and requires replication.
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Table 4 Credibility of the subgroup effect of STIR3 (per protocol)
Criterion/evaluation Comment
(1) Is the subgroup variable a characteristic measured at
baseline or after randomisation?
Yes, at baseline.
(2) Is the effect suggested by comparisons within rather than
between studies?
Yes, within this study.
(3) Was the hypothesis specified a priori? Yes, in the trial protocol and statistical analysis plan
(4)Was the direction of the subgroup effect specified a priori? Yes, and the a priori specified direction was verified
(5) Was the subgroup effect one of a small number of
hypothesised effects tested?
Yes, the hypothesis was predefined as primary hypothesis for this study and pre-ordered
as hypothesis six (F) in trial protocol
(6) Does the interaction test suggest a low likelihood that
chance explains the apparent subgroup effect?
Yes, p = 0.008, equal to the Bonferroni adjusted alpha of 0.05/6; this strengthened the
result, as the six tests were not independent
(7) Is the significant subgroup effect independent? Probably. The subgroup effect only changed from 5.1 to 4.5 RMDQ points when
analysing its independence
(8) Is the size of the subgroup effect large? Yes, 5.1 RMDQ points (predefined minimal clinically important value was 4), but its
95% CI was wide (1.9 to 8.2)
(9) Is the interaction consistent across studies? Not clear, no other study has examined this interaction
(10) Is the interaction consistent across closely related
outcomes within the study?
Partly, consistent across the closely related disability outcomes RMDQ and ODI, but not
significant for LBP intensity
(11) Is there indirect evidence that supports the hypothesised
interaction (biological rationale)?
Partly. Discitis can cause MCs, type 1 MCs can be symptomatic, amoxicillin tended to
reduce disability in patients with type 1 MCs (oedema) (see text). STIR3 group
(extensive oedema) improved most during antibiotic treatment, like verified
Cutibacterium acnes discitis (see text). No tissue samples taken to verify infection.
Further evidence (e.g. biological) needed to link extent of oedema on STIR to
likeliness of disc infection
Comparison of treatment groups STIR3 treatment groups were similar in clinical baseline characteristics and in
concomitant treatment during study, supporting the subgroup effect
Responder analyses STIR3: NNT 3–4 to achieve > 30–75% improved RMDQ from baseline to 1-year
follow-up, but wide CIs
Treatment effect over time Small numbers, wide CIs. Most improvement during antibiotic treatment as in verified
disc infection. Small changes in placebo group difficult to evaluate; might relate to
un-blinding, see below
Scatterplot of change in RMDQ score Change in RMDQ score at 1 year varied a lot within STIR3 amoxicillin group, indicating
inconsistent subgroup effect
Bangs blinding index In amoxicillin group − 0.01 (no un-blinding); in placebo group 0.61, i.e. possible
un-blinding, which may have impaired improvement—or lack of improvement may
have caused high blinding index
The 11 criteria were defined by Sun et al [34]
STIR, short tau inversion recovery; RMDQ, Rolland-Morris Disability Index; CI, confidence interval; ODI, Oswestry Disability Index; LBP, low back
pain; MCs, Modic changes; NNT, number needed treat
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Methodology
• prospective
• randomised controlled trial (subgroup analysis)
• multicentre study
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